Jacobs Bruce N. 4

What Happened

• Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics (KYMR), exercised stock options to acquire 61,378 shares at $5.33 per share (total cost ~$327,145). On the same day (2026-06-30) he sold approximately 77,109 shares in multiple open‑market transactions for aggregate proceeds of about $8.86 million. The filing also shows a disposition of 61,378 derivative shares at $0.00, consistent with a net/cashless settlement related to the option exercise.

Key Details

• Transaction date: 2026-06-30; Form 4 filed 2026-07-02 (timely).
• Option exercise: 61,378 shares acquired at $5.33 each (total ~$327,145).
• Open‑market sales: ~77,109 shares sold in multiple trades; total proceeds ≈ $8,864,829. Individual sale price ranges are noted in footnotes (roughly $110.37 to $118.09 depending on the lot; one weighted average range $117.55–$118.09).
• Notable footnotes: trades were effected under a Rule 10b5‑1 trading plan dated March 23, 2026 (F1); shares underlying the option were fully vested (F11); reported share counts include 373 ESPP shares (F2).
• Shares owned after the transactions: the excerpt provided does not list a total post‑transaction beneficial ownership number; the filing notes the reported count includes 373 ESPP shares.

Context

• This is a common insider pattern: exercising vested options and selling shares, much of it executed under a pre-established 10b5‑1 plan (reducing concerns about timing). The zero‑dollar derivative disposition indicates a net or cashless aspect of the option exercise (shares used to satisfy option exercise/withholding). These are routine executive liquidity events; purchases generally carry more interpretive weight than sales.